机构风向标 | 鹭燕医药(002788)2025年三季度已披露持仓机构仅3家

Core Viewpoint - Luyuan Pharmaceutical (002788.SZ) reported its Q3 2025 results, highlighting a total institutional ownership of 145 million shares, representing 37.29% of the company's total equity, with a slight decrease in institutional holding compared to the previous quarter [1] Institutional Ownership - As of October 26, 2025, three institutional investors disclosed their holdings in Luyuan Pharmaceutical, with a combined shareholding of 145 million shares, accounting for 37.29% of the total equity [1] - The institutional ownership ratio decreased by 0.12 percentage points compared to the previous quarter [1] - The institutional investors include Xiamen Meidiken Technology Co., Ltd., Xiamen Santai Technology Co., Ltd., and China Merchants Fund Management Co., Ltd. - Social Security Fund 1903 Combination [1] Public Fund Disclosure - In this reporting period, 44 public funds were disclosed, including notable funds such as Guojin Quantitative Multi-Factor A, Everbright Prudential Quantitative Stock A, and Guojin CSI A500 Index Enhanced A [1] Social Security Fund - One new social security fund disclosed its holdings in Luyuan Pharmaceutical, specifically the China Merchants Fund Management Co., Ltd. - Social Security Fund 1903 Combination [1] Foreign Investment - The report indicates that there was a lack of new disclosures from foreign institutions, with Barclays Bank PLC being the only foreign institution not disclosing holdings compared to the previous quarter [1]